

Curriculum Vitae

Morten Blaabjerg, Professor, MD, PhD

Education:

- Specialist authorization (Neurology): November 2013
- Ph.D. (Neurobiology): November 2003, Anatomy and Neurobiology, University of Southern Denmark (SDU). Title "Metabotropic Glutamate Receptors: Induction and modulation of excitotoxicity"
- MD: January 2006. SDU, Odense, Denmark
- Research Management Course, Copenhagen Business School, Denmark (2016-2017)
- Specialist Course in Movement Disorders, Scandinavian Movement Disorder Society (2017)

Professional experience:

Current positions:

- Chief physician (research), Dept. of Neurology, Odense University Hospital, From 2022-present
- Head of Research, Dept. of Neurology, Odense University Hospital, From 2022-present
- Clinical professor: Dept. of Clinical Research, University of Southern Denmark, From 2020-present

Former positions:

- Consultant: Dept. of Neurology, Odense University Hospital, Odense Denmark, 2020- 2022
- Associate professor: Dept. of Clinical Research, University of Southern Denmark, From 2015- 2020
- Consultant: Dept of Neurology, Rigshospitalet, Copenhagen From 2019- 2020
- Consultant: Dept of Neurology, Odense University Hospital (OUH). From 2017- 2019
- Consultant: Dept of Neurology, Zealand University Hospital (ZUH), Denmark, From 2016- 2017
- Consultant: Dept of Neurology, Odense University Hospital (OUH). From 2015- 2016
- Staff Neurologist: Dept of Neurology, Odense University Hospital. From 2013- 2015
- Clinical associate professor: Inst of Clinical Research, University of Southern Denmark. From 2010-2014

Management experience:

- Head of research, Department of Neurology, Odense University Hospital, from 2022-
- Member of European Academy of Neurology Scientific Panel, Translational Neurology.
- Member of board in Danish Society for Movement Disorders: From 2015
- Administrator of national guidelines in movement disorders and dementia
- Member of steering committee on national treatment guidelines (nNBV)
- Member of research committee, Danish Parkinson Foundation. From 2018-
- Member of research committee, Danish MS foundation. From 2022-
- Member of the research committee at Odense University Hospital

Research supervision

Supervision of student research projects:

Main supervisor or co-supervisor on 28 undergraduate and 6 PhD projects

Currently main supervisor on two ongoing PhD projects and two undergraduate research projects and co-supervisor on three PhD projects.

Publication statistics: 156 peer-reviewed publication. *h*-index = 32; Citation 3785 (Feb 2025 RG) 4 manuscripts submitted, 4 book chapters, 4 national guidelines

Selected publications:

1: Binks SNM et al., Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis. *Ann Clin Transl Neurol.* 2024 Feb 1. doi: 10.1002/acn3.52006. Epub ahead of print. PMID: 38303486.

2: Ryding M et al., Pathophysiological Effects of Autoantibodies in Autoimmune Encephalitides. *Cells.* 2023 Dec 20;13(1):15. doi: 10.3390/cells13010015. PMID: 38201219; PMCID: PMC10778077.

3: Nissen MS et al., CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study. *Front Immunol.* 2021 Dec 16;12:719432. doi: 10.3389/fimmu.2021.719432. PMID: 34975832; PMCID: PMC8716734.

4: Gaig C et al., Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. *Neurology.* 2021 Aug 11;97(14):e1367–81. doi: 10.1212/WNL.00000000000012639. Epub ahead of print. PMID: 34380749; PMCID: PMC8520389.

5: Nissen MS et al., NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study. *J Neurol.* 2022 Mar;269(3):1618-1630. doi: 10.1007/s00415-021-10738-9. Epub 2021 Aug 5. PMID: 34351472.

6: Ryding M et al., Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons. *Cells.* 2021 Apr 8;10(4):837. doi: 10.3390/cells10040837. PMID: 33917676; PMCID: PMC8068068.

7: Nissen MS et al., Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment. *CNS Neurol Disord Drug Targets.* 2020;19(8):584-598. doi: 10.2174/1871527319666200708133103. PMID: 32640967.

8: Nissen MS et al., Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature. *Front Neurol.* 2019 Oct 2;10:1056. doi: 10.3389/fneur.2019.01056. PMID: 31632341; PMCID: PMC6783555.